logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
2/11/2021 8:05:31 AM Alnylam Q4 GAAP Loss/Shr $2.09 Vs Loss $2.47 Prior Year
1/7/2021 7:05:29 AM Alnylam Reports Positive Topline Results From HELIOS-A Phase 3 Study Of Vutrisiran
12/21/2020 8:03:21 AM Alnylam Appoints Tolga Tanguler As Chief Commercial Officer
12/15/2020 7:03:56 AM Alnylam Says Remains On Track To Report Topline Results From The HELIOS-A Study Of Vutrisiran In Early 2021
12/3/2020 8:09:52 AM Alnylam Reports Full Patient Enrollment In Its ILLUMINATE-C Phase 3 Study Of Lumasiran
12/3/2020 8:08:50 AM Orsini Specialty Pharmacy Expands Partnership With Alnylam As A Limited Distribution Partner For OXLUMO
11/24/2020 7:09:49 AM Alnylam Announces Innovative Value-Based Agreement Framework For OXLUMO
11/24/2020 7:06:47 AM Alnylam: FDA Approves OXLUMO For PH1 To Lower Urinary Oxalate Levels In Pediatric, Adult Patients
11/19/2020 7:05:37 AM Alnylam Pharma: European Commission Grants Marketing Authorization For OXLUMO For Primary Hyperoxaluria Type 1
11/13/2020 9:03:30 AM Alnylam Announces Positive Interim Data From Ongoing Phase 1 Study Of ALN-AGT